Alkermes Shares Jump 6.5% After ADHD Drug Shows Clinical Proof-of-Concept
finance.biggo.com
Alkermes plc's stock rose 6.5% after its ADHD drug ALKS 7290 showed clinically meaningful symptom improvement in a Phase 1b trial, marking the first evidence of an orexin 2 receptor agonist's efficacy in treating adult ADHD. The drug demonstrated dose-dependent reductions in ADHD symptoms and improved disease severity with a favorable safety profile. A Phase 2 study is currently underway, with results expected in 2027.
All articles from 22 September 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.